Clinical Trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Name: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — clinical trial record (NCT04176198)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Protocol Amendment History 1 change

notable Trial sites expanded: 84 -> 90 locations 2026-08-04

Trial Details

NCT Number	NCT04176198
Lead Sponsor	Sumitomo Pharma America, Inc.
Conditions	Myelofibrosis
Enrollment	240 participants
Start Date	2019-12-16
Primary Completion	2027-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-03